Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-week, Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, Placebo-controlled Study of Fevipiprant Once Daily Plus Standard-of-care (SoC) for Reduction of Systemic Corticosteroids (Oral and Parenteral) Use in Patients With Severe Asthma

Trial Profile

A 52-week, Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, Placebo-controlled Study of Fevipiprant Once Daily Plus Standard-of-care (SoC) for Reduction of Systemic Corticosteroids (Oral and Parenteral) Use in Patients With Severe Asthma

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Feb 2019

At a glance

  • Drugs Fevipiprant (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 04 Sep 2018 Planned number of patients changed from 750 to 669.
    • 04 Sep 2018 Planned End Date changed from 17 May 2021 to 27 May 2021.
    • 04 Sep 2018 Planned primary completion date changed from 17 May 2021 to 27 May 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top